Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Intercept blood system: Phase III; marketed in EU

CERS and partner BAX will begin a supplemental platelet transfusion study of their Intercept pathogen inactivation system

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE